Studies have shown that in the receptor tyrosine kinase (RTK)-RAS pathway, irrespective of tumor types, Kirsten rat sarcoma (KRAS) is the most frequently altered gene, followed by BRAF, and EGFR41. This evidence concerns the gene NTRK1 and neoplasm.